Browse Category

NASDAQ:CRSP News 23 January 2026

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

New York, Jan 23, 2026, 05:47 (EST) — Premarket CRISPR Therapeutics AG shares slipped about 0.5% to $60.51 in premarket trading on Friday, following a sharp 11.1% gain the previous day. The stock closed at $60.81 on Thursday after hitting an intraday high of $60.86 and seeing over 3.4 million shares change hands. Investors were reacting to an insider-sale filing.…

Stock Market Today

  • Oric Pharmaceuticals Shares Poised for 74% Upside as Biotech Innovation Draws Investor Attention
    January 23, 2026, 8:13 AM EST. Oric Pharmaceuticals (NASDAQ: ORIC) is gaining investor interest with a potential 74% upside from its current $12.05 share price, backed by partnerships with Pfizer, Bayer, and Johnson & Johnson. The clinical-stage biotech focuses on therapies addressing cancer treatment resistance, advancing candidates like ORIC-114 and ORIC-944 through early-stage trials. Despite a $1.17 billion market cap, Oric reports a negative EPS of -1.71 and free cash flow of -$70.7 million, reflecting typical high-risk biotech dynamics. With no dividends and a neutral RSI, stock momentum shows cautious optimism. Analysts rate ORIC with 14 buys and project a $21 average target price, suggesting substantial growth for investors able to tolerate the sector's inherent uncertainties.
Go toTop